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Abstract 
Purpose: To study the effect of Clematis chinensis extract (CCE) on diabetic nephropathy in rats. 
Methods: Eight-week old male Wistar rats were injected with streptozotocin to induce diabetes. The 
effects of CCE(250 or 500 mg/kg) on renal function index, fasting blood glucose (FBG), blood fat, 
oxidation index, and pathological kidney changes for 3 weeks were compared to those of the positive 
control drug, captopril. 
Results: At 12 weeks, CCE(500 mg/kg) treatment had significantly decreased serum blood urea 
nitrogen (BUN, 12.61 ± 1.42 mmol/L), serum creatinine (SCr, 84.64 ± 6.37 μmol/L), creatinine clearance 
(CCr, 0.88 ± 0.10 mmol/L), interleukin-6 (IL-6, 297.56 ± 19.62 pg/mL), urinary albumin, urinary albumin 
excretion rate (UAER, 11.68 ± 0.97 μg/min), kidney hypertrophy index (kidney weight/body weight, 0.58 
± 0.03%) and FBG (11.51 ± 0.96 mmol·L-1). It significantly decreased triglyceride (TG, 0.26 ± 0.05 
mmol/L), total cholesterol (TC, 1.52 ± 0.06 mmol/L) and low-density lipoprotein-cholesterol (LDL-c, 0.71 
± 0.06 mmol/L) levels and increased high-density lipoprotein-cholesterol (HDL-c, 0.65 ± 0.05 mmol/L). 
CCE treatment also significantly decreased malondialdehyde (MDA, 16.14 ± 1.24 nmol/mgprot) levels 
and increased superoxide dismutase (SOD, 95.17 ± 4.06 U/mgprot) and glutathione peroxidase (GSH-
Px, 154.33 ± 11.76 mmol/L) (both p < 0.05). Finally, CCE reduced the degree of glomerular basement 
membrane and renal tubular thickening and swelling in diabetic rats. 
Conclusion: CCE has a significant inhibitory effect on diabetic nephropathy-induced renal injury in rats. 
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Diabetic nephropathy (DN) is a frequent and 
major microvascular complication of diabetes 
mellitus and is the most common cause of end-
stage renal failure disease in many countries [1]. 
Several factors such as hyperglycemia, 
hyperlipidemia, oxidative stress, and 
inflammatory cytokines contribute to renal 
damage progression in DN. While both types 1 
and 2 diabetes mellitus can lead to DN, it is more 
common with the latter [2]. DN is characterized 
by glomerular and tubular hypertrophy, basement 
membrane thickening, extracellular matrix 
component accumulation, glomerulosclerosis, 
and tubulo-interstitial fibrosis in the mesangium 
and interstitium [3]. 
 
Traditional herbal medicines are widely used in 
different countries. Medicinal plants are used as 
therapies for multiple diseases including DN 
[4,5]. For example, Sefi et al showed that 
Artemisia campestris leaf extract prevented DN 
by attenuating oxidative and nitrosative stress 
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[6]. It was reported that Clematis chinensis could 
improve kidney damage and exert significant 
protection against DN [7,8]. The aim of this study 
was to examine the effect of CCE on DN 
progression in high-fat diet and streptozotocin 






Herbal samples of Clematis chinensis were 
collected from Bozhou City, Anhui Province in 
China in July 2014. The taxonomic identification 
of the plant was performed by Professor Jin-ke 
Liu of the pharmacy department at Shandong 
University, China. A voucher specimen (No. CCE 
201308024) was deposited in the herbarium of 
Shandong University, China for future reference. 
 
Three batches of Clematis chinensis were dried 
in an oven, and an aqueous extract was obtained 
by steeping the dried herb in water at 60 °C for 3 
h. The extracted fluid was dried in an oven and 
freeze-dried; 1 g powder was equivalent to about 
1.8 g of the plant (53.28 % yield). 
 
Animals and grouping 
 
Eight-week-old male Wistar rats (weighing 300–
350 g) were provided by the Experimental Animal 
Center of Shandong Province (Certificate no. 
SYXK2004-0003). The animals had free access 
to feed and water and were allowed to 
acclimatize for at least 1 week before use. The 
protocol was approved by the Animal Care and 
Use Committee of Shandong University 
(Approval ref no. 20120907) and was carried out 
in compliance with the Directive 2010/63/EU on 
the handling of animals used for scientific 
purposes [9]. 
 
The rats were randomly divided into five groups 
of 10 rats: control, model, model with positive 
drug (10 mg/kg captopril), and model with CCE 
(250 and 500 mg/kg doses). CCE was 
intragastrically administered daily for 3 weeks. All 
drugs were dissolved in water before they were 





After 1 week of acclimatization, the rats were 
randomly divided into two groups: control and 
high-fat diet (HFD). The HFD consisted of 40 % 
fat, 41 % carbohydrate, and 18 % protein for 8 
weeks. After an overnight fast, HFD-fed rats 
were injected intravenously (iv) with a single 30-
mg/kg dose of streptozotocin (STZ) (Sigma, St. 
Louis, MO, USA), while control rats were injected 
with vehicle citrate buffer. Two weeks after STZ 
injection, the rats were killed by carbon dioxide 
suffocation. Blood samples were collected 
through the tail vein, and plasma glucose levels 
were measured with a glucometer (Eumed Bio-
technology Co., Ltd., Taiwan, China). Rats with 
fasting blood glucose (FBG) >11.1 mmol/L [10] 




Serum samples were collected by eyeball 
removal, and used to measure total cholesterol 
(TC), triglyceride (TG), high-density lipoprotein-
cholesterol (HDL-c), low-density lipoprotein-
cholesterol (LDL-c), serum creatinine (SCr), 
blood urea nitrogen (BUN), and interleukin-6 (IL-
6). Assessments were performed accord to the 
manufacturer’s protocols for each diagnostic kit 
(all from Shenzhen Xin-Bo-Sheng Biological 
Technology Co. Ltd., Shenzhen, China). 
 
Renal cortex assessments 
 
After the rats were sacrificed by cervical 
dislocation, the renal cortex was homogenized 
with ice-cold normal saline (W:V = 1 g:9 mL), and 
the homogenates were centrifuged at 3500 rpm 
for 10 min at 4 °C. Superoxide dismutase (SOD) 
activity and malondialdehyde (MDA) and 
glutathione peroxidase (GSH-Px) levels were 
measured with commercially available kits 
(Shenzhen Xin-Bo-Sheng Biological Technology 




The concentrations of albumin and creatinine in 
urine samples were determined with commercial 
assay kits (Nanjing Jiancheng, Institute of 
Biotechnology, Nanjing, China). Creatinine 
clearance (CCr) and 24-h urinary albumin 
excretion rate (UAER) were calculated according 
to the following formulas:  
 
UAER = urinary albumin (l g/mL)/24-h urine 
volume (mL).  
 
CCr = urinary creatinine (mg/mL)/creatinine in 




After the rats were sacrificed by cervical 
dislocation method, kidney samples were fixed in 
10 % phosphate-buffered formalin, dehydrated, 
and then embedded with paraffin. Sections about 
4-μm-thick were prepared from each embedded 
tissue and stained with hematoxylin-eosin (HE). 
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The prepared slides were examined under a light 
microscope at 400× magnification by a 
pathologist who was blinded to the experimental 
conditions. A 1-mm3 portion of kidney was fixed 
in 4 % glutaraldehyde in sodium phosphate 
buffer (0.2 M, pH 7.4) for 3 h at 4 °C. Tissue 
samples were washed with the same buffer and 
postfixed in 1 % osmium tetroxide in 0.1 % 
sodium phosphate buffer (0.2 M, PH 7.4) at 4 °C. 
The samples were washed with the same buffer 
for 3 h at 4 °C again, and then dehydrated with 
graded ethanol. Samples were embedded with 
resin and polymerized at 72 °C for 48 h. Ultra-
thin sections (50-70 nm) were stained with uranyl 
acetate and lead acetate, and images were 
captured with a JEM 1200 EX electron 




Values are presented as mean ± standard 
deviation (SD). Results were analyzed 
statistically by one-way analysis of variance 
(ANOVA) followed by Tukey’s multiple 
comparison using SPSS 16.0 software for 
Windows (SPSS Inc., Chicago, IL, USA). 
Differences were considered statistically 




Effect of CCE on FBG in diabetic rats 
 
As indicated in Table 1, FBG levels were 
measured after 12-h fasts at the beginning of the 
experiment and weeks 3, 6, 9, and 13. At 
baseline, the diabetic rats had high FBG, which 
significantly increased throughout the 
experimental period (p < 0.01). From the third 
week, CCE (250, 500 mg/kg) significantly 
decreased FBG (p < 0.05), while captopril (10 
mg/kg) had no notable effect (p > 0.05). 
 
Effect of CCE on BUN, SCr, CCr, and IL-6 in 
diabetic rats 
 
As indicated in Table 2, BUN, SCr, and IL-6 
levels were significantly increased in diabetic rats 
compared to control rats, while the CCr level was 
decreased (all p < 0.05). Following CCE 
treatment or captopril treatment, BUN and SCr 
decreased, while CCr increased (p < 0.05) 
compared with the diabetic group. IL-6 levels 
significantly decreased in the high-dose CCE 
(500 mg/kg) and captopril groups compared with 
the diabetic group; however, no significant 
difference was found between the low-dose CCE 
(250 mg/kg) and diabetic groups. 
 
Effect of CCE on renal function markers in 
diabetic rats 
 
As indicated in Table 3, renal function markers, 
urinary albumin, UAER, and kidney weight/body 
weight (KW/BW) were all significantly increased 
in the diabetic group compared with the control 
group (p < 0.01). CCE (both doses) and captopril 
significantly reduced urinary albumin, UAER and 
KW/BW compared with diabetic rats (p < 0.05). 
 
      Table 1: Effect of CCE on FBG (mmol·L-1) 
 
Group Dose (mg/kg) Baseline 3 weeks 6 weeks 9 weeks 12 weeks 
Control — 5.16±0.21 4.97±0.18 5.09±0.15 5.17±0.12 5.22±0.14 
Model — 19.24±1.31## 18.34±1.53## 17.59±1.24## 21.56±1.75# 18.74±1.65## 
Captopril 10 19.31±1.17 17.38±1.32 17.85±1.28 20.14±1.18 18.43±1.34 
CCE-L 250 19.28±1.24 13.27±1.07* 12.85±1.06* 13.06±1.12* 12.97±1.15* 
CCE-H 500 19.25±1.27 11.14±0.95** 11.32±0.86* 11.42±1.08* 11.51±0.96* 
CCE, Clematis chinensis extract; CCE-H, high dose of CCE; CCE-L, low dose of CCE; FBG, fasting blood 
glucose. #P<0.05, ##P<0.01 vs. control group; *P<0.05, **P<0.01 vs. model group 
 
Table 2: Effect of CCE on BUN, SCr, CCr, IL-6 in diabetic rats 
 
Group Dose BUN SCr CCr IL-6 
  (mg/kg) (mmol/L) (μmol/L) (mmol/L) (pg/mL) 
Control — 4.15±0.16 78.92±4.83 1.14±0.18 182.49±12.51 
Model — 19.27±1.33## 121.39±6.87## 0.57±0.06## 394.53±28.61## 
Captopril 10 11.94±1.76* 83.74±7.22* 0.94±0.09* 282.36±24.83* 
CCE-L 250 14.35±1.57* 85.94±8.31* 0.92±0.11* 324.18±26.76 
CCE-H 500 12.61±1.42* 84.64±6.37* 0.88±0.10* 297.56±19.62* 
BUN, blood urea nitrogen; CCE, Clematis chinensis extract; CCE-H, high dose of CCE; CCE-L, low dose of 
CCE; CCr, creatinine clearance; IL-6, interleukin 6; SCr, serum creatinine;  #p < 0.05, ##p < 0.01 vs. control 
group; *p < 0.05, **p < 0.01 vs. model group 
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         Table 3: Effect of CCE on urinary albumin, UAER and KW/BW in diabetic rats 
 
Group Dose Urinary albumin UAER KW/BW 
  (mg/kg) (mg/L) (μg/min) (%) 
Control — 194.56±25.73 5.37±0.59 0.37±0.04 
Model — 327.41±22.44## 16.34±1.57## 0.82±0.07## 
Captopril 10 227.34±25.12* 10.54±1.13* 0.56±0.03* 
CCE-L 250 237.24±26.49* 12.37±1.29* 0.65±0.04* 
CCE-H 500 219.36±24.18* 11.68±0.97* 0.58±0.03* 
CCE, Clematis chinensis extract; CCE-H, high dose of CCE; CCE-L, low dose of CCE; KW/BW, 
kidney weight/body weight; UAER, urinary albumin excretion rate; #p < 0.05, ##p < 0.01 vs. control 
group; *p < 0.05, **p < 0.01 vs. model group 
 
   Table 4: Effect of CCE on blood lipid levels 
 
Group Dose TC TG HDL-c LDL-c 
  (mg/kg) (mmol/L) (mmol/L) (mmol/L) (mmol/L) 
Control — 1.45±0.07 0.24±0.04 0.69±0.06 0.52±0.06 
Model — 2.47±0.11# 0.47±0.06# 0.37±0.03## 1.24±0.09# 
Captopril 10 1.69±0.17 0.41±0.07 0.48±0.06 0.92±0.12 
CCE-L 250 1.89±0.14 0.36±0.05 0.62±0.05* 0.79±0.07* 
CCE-H 500 1.52±0.06* 0.26±0.05* 0.65±0.05* 0.71±0.06* 
CCE, Clematis chinensis extract; CCE-H, high dose of CCE; CCE-L, low dose of CCE; HDL-c, 
high-density lipoprotein-cholesterol; LDL-c, low-density lipoprotein-cholesterol; TC, total 
cholesterol; TG, triglyceride; #p < 0.05, ##p < 0.01 vs. control group; *p < 0.05, **p < 0.01 vs. 
model group 
 
        Table 5: Effect of CCE on oxidative parameters in diabetic rats 
 
Group Dose SOD MDA GSH-Px 
  (mg/kg) (U/mgprot) (nmol/mgprot) (mmol/L) 
Control — 102.35±5.12 12.76±0.85 162.76±11.27 
Model — 78.42±3.14## 24.58±1.13## 108.39±10.14# 
Captopril 10 94.27±4.28* 15.43±1.37* 148.37±14.26* 
CCE-L 250 84.29±4.92 19.67±1.45 128.46±12.43 
CCE-H 500 95.17±4.06* 16.14±1.24* 154.33±11.76* 
CCE, Clematis chinensis extract; CCE-H, high dose of CCE; CCE-L, low dose of CCE; GSH-Px, glutathione 
peroxidase; MDA, malondialdehyde; SOD, superoxide dismutase; #p < 0.05, ##p < 0.01 vs. control group; *p < 
0.05, **p < 0.01 vs. model group 
 
Effect of CCE on blood lipid levels 
 
As in Table 4, diabetic rats exhibited 
hyperlipidemia. Compared with control rats, TC, 
TG, and LDL-c levels were increased, while 
HDL-c level was decreased (all p < 0.05). High-
dose CCE significantly reduced TC, TG, and 
LDL-c and increased HDL-c compared with the 
diabetic group (all p < 0.05). The HDL-c level 
was increased significantly and the LDL-c level 
was decreased (p < 0.05) compared with the 
diabetic group, in the CCE group (250 mg/kg). 
Captopril treatment did not significantly affect 
blood lipid levels (p > 0.05). 
 
Effect of CCE on oxidative parameters in 
diabetic rats 
 
SOD and GSH-Px activities were significantly 
decreased, and the MDA content in the renal 
cortex was significantly increased compared with 
control rats (all p < 0.05). High-dose CCE and 
captopril normalized SOD and GSH-Px activities 





Fig 1 shows photomicrographs of glomeruli from 
each group stained with HE. Kidney sections 
from diabetic rats (Fig. 1b) showed reduced 
glomerular tuft diameter, balloon adhesion, wall 
thickening, decreased glomerular volume, tubular 
vacuolization, and dilation. In contrast, kidney 
lesions in both CCE groups (Fig. 1c, Fig. 1d) and 
the captopril group (Fig. 1e) were significantly 
improved. 
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Figure 1: Effect of CCE on kidney histomorphology; A: control; B: model; C: CCE (250 mg·kg-1); D: CCE (500 




Our study provides novel evidence of the 
protective effects of CCE against DN in an 
experimental model of type 2 diabetes. 
Consuming an HFD can induce insulin resistance 
[15], primarily through the Randle or glucose-
fatty acid cycle [16]. High TG levels due to 
excess fat intake can lead to the preferential use 
of fatty acids for oxidation; this can blunt the 
insulin-mediated suppression of hepatic glucose 
output and reduce glucose uptake and utilization 
in skeletal muscle, leading to compensatory 
hyperinsulinemia, a common feature of insulin 
resistance [17-18]. Plasma lipids, insulin levels, 
and hepatic lipid content are not significantly 
affected in these animals. An HFD plus a 
relatively moderate STZ dose can mimic the 
natural history and metabolic characteristics of 
patients with type 2 diabetes. We started treating 
the diabetic rats 2 weeks after STZ injection, 
which is more reflective of DN in diabetic rats. 
Hyperglycemia, hyperlipidemia, oxidative stress, 
and renal injuries all manifested in our model 
system.  
 
DN is one of the most serious complications of 
diabetes and is characterized by elevated SCr, 
BUN, 24 h-UAER, CCr, as well as kidney 
hypertrophy. Albuminuria is a marker of DN [19], 
and urinary albumin excretion is considered the 
best clinical predictor of renal lesions in DN [20]. 
Creatinine is a breakdown product of creatinine 
phosphate in muscles, and its clearance is an 
indicator of glomerular filtration rate. In this study, 
increased urinary albumin corresponding to the 
hyperglycemia was notable 13 weeks after 
diabetes induction. Furthermore, renal function 
markers CCr, KW/BW, SCr, and BUN were 
pathologically elevated in diabetic rats. Daily 
CCE treatment for 13 weeks ameliorated these 
symptoms of DN progression in diabetic rats. 
 
In the diabetic group, we observed morphological 
changes including glomerular lesions ultra-
structural glomerular endothelium damage, and 
thickening of podocyte processes and the 
basement membrane. Histological examination 
showed that CCE evidently alleviated DN 
progression. In type 2 diabetes, DN is 
characterized by dyslipidemia in addition to 
dysfunctional glucose metabolism. 
Hyperglycemia enhances glomerulosclerosis and 
accelerates DN progression. Dysregulation of 
serum lipid parameters including TG, TC, HDL-c, 
and LDL-c are common in diabetes [21]. Results 
of in vitro and in vivo studies strongly suggest 
that many biochemical and histological 
abnormalities seen in glomerulosclerosis are 
analogous to those observed in atherosclerosis 
[22]. Hyperlipidemia promotes DN development, 
and diabetes aggravates dyslipidemia [23], 
perpetuating a vicious cycle. In this study, the 
diabetic rats showed increased levels of TG, TC, 
and LDL-c and decreased HDL-c. The lipid 
metabolites in diabetic rats were improved by 
high-dose CCE (500 mg/kg). 
 
Some studies have reported that modulating 
tissue or plasma lipid levels decreases the risks 
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of microvascular disease and related 
complications [24]. Notably, one group showed 
that CCE had the potential to normalize lipid 
metabolism [25]. Accordingly, CCE may prevent 
DN by ameliorating dyslipidemia. 
 
Uncontrolled hyperglycemia can produce high 
levels of reactive oxygen species (ROS), which 
are a major factor in diabetes pathogenesis [26]. 
Recent studies have confirmed that enhanced 
oxidative stress and increased ROS production 
play important roles in many diseases [27]. The 
human body possesses two types of antioxidant 
systems: the first includes SOD, catalase (CAT), 
and GSH-Px, and the second comprises 
nonenzymatic antioxidant systems. Compared to 
the DN model group, antioxidant enzyme 
activities (SOD and GSH-Px) were dose-
dependently enhanced in the CCE group, while 
MDA levels decreased in the renal cortex. These 
results indicate that CCE could attenuate 
oxidative damage in the kidney and alleviate DN 
by increasing antioxidant activities and 




CCE can ameliorate kidney damage in diabetic 
rats. Further studies are needed to clarify the 
mechanism by which CCE protects against DN; 
possibilities include glucose regulation, lipid 
metabolism and oxidative stress, and 
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